Blog

Becomes the World’s Only Driver Monitoring System Validated Under Both Indian and EU Safety Standards

NEW YORK, NY / ACCESS Newswire / October 7, 2025 / New to The Street, one of America’s longest-running business television brands airing as sponsored programming on Fox Business and Bloomberg, congratulates its client partner Roadzen Inc. (NASDAQ:RDZN) on a historic milestone for its flagship platform, DrivebuddyAI.

DrivebuddyAI has secured validation for compliance with the European Union’s General Safety Regulation (EU GSR 2144) from Applus IDIADA in Barcelona, making it the world’s only AI-powered Driver Monitoring System (DMS) validated under both India’s AIS-184 and EU safety standards.

This breakthrough solidifies Roadzen’s global leadership in AI-driven mobility and insurance technology, aligning with the upcoming EU NCAP 2026 mandate, which will require in-cabin driver monitoring in all new vehicles beginning July 2026.

Key Highlights

• Dual Certification: Only driver monitoring platform validated under both Indian (AIS-184) and EU (GSR 2144) safety frameworks.

• 3.5 Billion+ Kilometers of Data: DrivebuddyAI has surpassed 3.5 billion kilometers of real-world driving data-nearly doubling within four months.

• 70%+ Accident Reduction: Proven AI efficacy with over 70% fewer accidents through advanced behavioral modeling and alert accuracy.

• Global Showcase: DrivebuddyAI will exhibit live at InCabin Europe 2025 (Booth C210) in Barcelona, October 7-9, featuring live demos across DMS, ADAS, ADDW, DDAW, and occupant monitoring.

Leadership Commentary

Nisarg Pandya, Head of Roadzen’s DrivebuddyAI, said:

“We’re proud to be the only company validated for both European and Indian standards. The industry is demanding higher accuracy and fewer false alerts – and DrivebuddyAI delivers exactly that. With validated compliance for DMS and our single-box, five-compliance solution, we’re fully prepared for the EU market.”

Rohan Malhotra, CEO of Roadzen, added:

“We’re building the world’s first truly global AI foundation model for road safety-trained on billions of miles of diverse driving data. Our platform is designed to make roads safer everywhere.”

About Roadzen Inc. (NASDAQ: RDZN)

Roadzen Inc. is a global technology leader at the intersection of AI, insurance, and mobility. Its technologies empower insurers, carmakers, and fleets to build new products, process claims faster, and improve road safety through telematics and computer vision. Recognized by Forbes, Fortune, and Financial Express as a top AI innovator, Roadzen operates across the U.S., U.K., and India with over 300 employees.
Visit www.roadzen.ai for more information.

About New to The Street

New to The Street is one of the nation’s longest-running business television brands, broadcasting weekly as sponsored programming on Fox Business and Bloomberg, reaching more than 220 million households. Through its Predictable Media™ model, New to The Street blends sponsored programming, earned media, and outdoor billboard dominance across Times Square and the NYC Financial District. Its YouTube channel, with over 3.5 million subscribers, provides unmatched digital distribution for its featured companies, making it the most integrated media platform for public and private companies globally.

Media Contact

Monica Brennan
New to The Street
Monica@NewToTheStreet.com

SOURCE: New To The Street

View the original press release on ACCESS Newswire

– Global Anti-Scam Alliance and Feedzai Release Global State of Scams 2025 –

THE HAGUE, NL / ACCESS Newswire / October 7, 2025 / The Global Anti-Scam Alliance (GASA), in partnership with Feedzai, has released the Global State of Scams 2025 Report. Based on a survey of 46,000 adults across 42 markets, the report provides a comprehensive analysis of the prevalence, impact, and policy challenges of scams worldwide.

In the past 12 months, 57 percent of adults worldwide experienced a scam and 23 percent lost money. Shopping scams affected 54 percent of victims, while investment scams and unexpected money scams each impacted 48 percent. Scam encounters were most frequent in South America, Africa, and Oceania, where up to one in four adults lost money in the last year.

The research also highlights the emotional toll of scams. 69 percent of victims reported (huge) stress as a result, while 17 percent reported a loss of confidence and 14 percent said scams created heightened tension within their family unit. Despite this, many scams remain unreported, with uncertainty over where to report being the main barrier.

93% of adults globally claim to take at least one step to verify if an offer is legitimate or not. However, many often rely on methods that are less effective such as checking for spelling and grammar errors (27%); looking for reviews on the same website (24%) and checking if the company is on social media (21%).

Despite nearly three quarters of adults globally feeling confident in their ability to recognise a scam, scams remain prevalent, with many scam victims losing money and a significant proportion never reporting their encounters.

Jorij Abraham, Managing Director of GASA, comments: “We have a huge challenge, 73 percent of people worldwide feel confident they can recognize scams, however, nearly a quarter still lost money in the past year. Scams are not only draining finances but also eroding trust and creating significant stress within families. We are learning that scam awareness campaigns alone are not enough. We need to continuously educate consumers, build better solutions to recognize and block (AI) scams and work internationally closer to get to catch the scammers.

“Fraud isn’t just about transactions anymore. It’s about intent. Criminals are exploiting trust, behavior, and technology in real time. Stopping them takes more than spotting anomalies; it takes understanding human patterns. No single bank or payment provider can do that alone. The only way forward is collaboration across financial institutions and cybersecurity teams. That’s how we protect consumers everywhere.” adds Nuno Sebastião, CEO, Feedzai

The Global State of Scams 2025 Report emphasizes that scams are no longer isolated crimes but a global threat to consumer safety, financial stability, and trust in digital economies. GASA and Feedzai call for stronger international collaboration, better scam prevention tools, and accountability across platforms, governments, and industries.

The full report can be downloaded here: https://www.gasa.org/research

SOURCE: Global Anti-Scam Alliance

Related Images

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / October 7, 2025 / Fashion brands have always been built on one primary characteristic: trust. Trust that the product is genuine. Trust that the craftsmanship is real. Trust that the values behind the brand match the ones it promotes. From Paris ateliers to fast-fashion retailers, every label’s reputation depends on that same promise of quality, consistency, and credibility.

But the world has changed. Supply chains have gone global. Sustainability has become a shareholder demand. And the old way of proving trust – through reputation alone – no longer cuts it. Today, trust must be earned through evidence. That’s where SMX (NASDAQ:SMX) and CETI, the European Center for Innovative Textiles, come in.

Together, they’ve created something fashion has needed for years: proof. Their industrial-scale collaboration embeds molecular-level traceability directly into textile fibers, giving every material its own unbreakable digital fingerprint. It’s DNA for fabric; a permanent identity that confirms where materials come from, how they were made, and whether they meet the sustainability claims printed on the tag. And for the first time, every brand, not just the luxury houses, can turn transparency into a competitive advantage.

A Measurement Problem, Not Faulty Intentions

Fashion doesn’t have a moral problem; it has a measurement problem. Even value-focused retailers have teams dedicated to quality control and sustainability. The intent is real, but the evidence hasn’t kept up. Supply chains sprawl across continents, crossing language barriers, time zones, and subcontractors until visibility fades. The result? Honest effort that still looks like greenwashing because no one can prove what’s real. SMX and CETI are changing that dynamic entirely.

Instead of auditing factories after the fact, their system embeds truth from the start. SMX’s patented molecular markers are added at the resin or polymer stage, before the first thread is spun. That proof lives within the fiber itself, surviving every step of production, from dyeing and weaving to retail. Yes, it works.

CETI’s validation lines in Lille have already demonstrated that this technology isn’t theoretical; it works on industrial machines, at industrial speeds. Proof no longer interrupts production. It powers it. That subtle shift – from inspection to integration – changes everything. A brand can now trace a fabric’s full journey from its thread origin to the finished garment and back through recycling, maintaining continuous accountability at every stage. Regulators can verify claims instantly. Stakeholders can see real ESG performance data. And consumers can finally trust that “sustainable” means something measurable, not just marketable.

Rewarding Through Monetization

But SMX doesn’t stop at validation; it monetizes verification. Through its blockchain-enabled Plastic Cycle Token (PCT), proof itself becomes an asset. The same mechanism that turns verified recycled plastics into tradeable digital credits now applies to textiles, transforming tons of verified fiber into quantifiable economic value.

The scale is staggering. We’re not talking about pennies per product. We’re talking about metric tons of authenticated material worth tens of thousands, even millions, when aggregated across global supply chains. For the first time, sustainability isn’t a cost center. It’s a profit driver. Proof doesn’t just protect brand equity; it compounds it.

That’s the genius of this partnership: SMX and CETI aren’t forcing fashion to reinvent itself. They’re giving it tools that fit seamlessly into the world it has already built: the infrastructure of design, logistics, and identity that has powered the industry for over a century. And they’re doing it at a moment when the stakes couldn’t be higher.

Timely to Meet EU Digital Product Passport Mandates

With the EU’s Digital Product Passport mandate set to take effect in 2026, every brand will soon be required to prove the origins, composition, and recyclability of its materials. Most companies are scrambling to figure out how. SMX and CETI already have the answer: a live, validated system that replaces paperwork with molecular proof and turns compliance into a competitive advantage.

The implications go far beyond regulation. Counterfeiting, fashion’s most persistent parasite, collapses when authenticity lives inside the material. A counterfeit can fake a label, but not a molecule. One scan verifies authenticity, origin, and sustainability simultaneously. For brands, that’s protection. For regulators, that’s enforcement. For consumers, that’s trust they can touch. And for e-commerce sellers, a single scan replaces armies of authenticators, eliminating human error and putting an unmistakable seal of legitimacy on every product. Buyers get the real deal, and seller platforms gain the biggest credibility boost in their history.

That’s the beauty of this SMX technology; it works for everyone. A couture house in Milan, a denim brand in Los Angeles, or a retailer in Bangkok. All can operate on the same foundation of verifiable truth. SMX and CETI have combined to offer a system that unites fashion’s two great ambitions: creativity and credibility.

Fashion built its empire on both quality and trust. Today, SMX and CETI are laying that trust on an unprecedented foundation – one where brands can replace promises with immutable and verifiable proof. Brands will continue to give consumers the logos. SMX and CETI will give them the ledger, not stitched on, but woven in. Those brands that embrace SMX and CETI’s contributions won’t just meet the standard; they’ll be a part of setting it. More importantly, protect brand pedigree at a level no one ever thought possible.

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of gold, steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

EMAIL: info@securitymattersltd.com

SOURCE: SMX (Security Matters)

View the original press release on ACCESS Newswire

Findings show that Telomir-1 restores the body’s natural tumor suppressor defenses by reversing abnormal DNA methylation of MASPIN and RASSF1A – genes that help block invasion, limit metastasis, and improve chemotherapy responsiveness in aggressive prostate cancer models.

MIAMI, FLORIDA / ACCESS Newswire / October 7, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) (“Telomir” or the “Company”), a preclinical-stage biotechnology company developing therapies that target epigenetic drivers of cancer, aging, and age-related disease, today announced new preclinical results showing that its investigational therapy Telomir-1 reactivated two of the body’s most important tumor suppressor genes, MASPIN (“tumor suppressor shield”) and RASSF1A (“guardian gene”; also called SERPINB5), through DNA methylation reset in prostate cancer models. By restoring the activity of these genes, Telomir-1 may help prevent cancer spread and improve chemotherapy response

Key New Findings

• MASPIN (“tumor suppressor shield”): MASPIN is a natural defense protein that blocks tumor invasion, regulates cell migration and angiogenesis, promotes apoptosis, and enhances treatment sensitivity. In an aggressive prostate-cancer model in vivo, MASPIN was silenced by DNA hypermethylation. Telomir-1 reversed the chemotherapy-induced DNA methylation to restore MASPIN activity, consistent with reactivation of this key tumor-suppressor pathway.

• RASSF1A (“guardian gene”, also called SERPINB5):
  RASSF1A is a critical regulator of cell cycle brakes, apoptosis, and suppression of metastasis. It is commonly silenced in aggressive cancers by hypermethylation. Telomir-1 reduced RASSF1A methylation in a dose-dependent manner, with stronger effects when combined with chemotherapy.

• Implication: These results suggest Telomir-1 may reactivate natural tumor defenses, counteract chemotherapy-induced resistance mechanisms, and help limit metastasis – two of the most persistent challenges in oncology.

Why This Matters

Metastasis is responsible for the vast majority of cancer deaths, and chemotherapy resistance remains a major barrier to durable responses. Tumors often silence genes like MASPIN and RASSF1A by hypermethylation to disable the body’s natural defenses.

Telomir-1’s ability to reset DNA methylation, restore tumor suppressor activity, and synergize with chemotherapy provides a compelling preclinical rationale for its potential as a first-in-class epigenetic reset therapy in oncology.

Scientific Perspective

“The potential reactivation of MASPIN and RASSF1A by inhibition of hypermethylation is highly significant because these genes play a central role in blocking tumor invasion, uncontrolled growth, and metastasis,” said Dr. Itzchak Angel, CSA at Telomir. “By demonstrating that in addition to an effect on DNA methylation of other key proteins, such as STAT1 and CDKN2A, Telomir-1 can also reset DNA methylation and restore the function of these silenced tumor suppressors, we are providing strong mechanistic evidence that this drug candidate could address cancer at its epigenetic roots in a broader manner.”

CEO Perspective

“These results highlight Telomir-1’s potential to change the way we think about treating cancer and aging,” said Erez Aminov, CEO of Telomir. “Instead of only managing disease progression; Telomir-1 may reset the underlying epigenetic programs that drive tumor growth, resistance, and cellular decline. By reawakening the body’s natural defenses, this approach could mark a new era in medicine – one where we target the root biology of cancer and age-related disease.”

Building on Prior Work

Telomir-1 has previously demonstrated in preclinical studies:

• Reactivating tumor suppressors such as STAT1 (immune surveillance), CDKN2A (cell cycle brake), and TMS1 (apoptosis mediator).

• Histone demethylase inhibition: activity across JMJD3 (KDM6B), UTX (KDM6A), FBXL10 (KDM2B), FBXL11 (KDM2A), and the KDM5 family – enzymes long considered undruggable despite their central role in cancer, inflammation, and resistance.

• Mitochondrial health restoration: improved energy production while reducing oxidative stress (ROS) and avoiding unwanted cell proliferation, suggesting relevance to cancer metabolism as well as Alzheimer’s, Parkinson’s, ALS, and Progeria.

• Wnt “fuel line” modulation: modest Tankyrase inhibition that may cut off cancer’s growth signaling without telomere-shortening toxicity.

• Selectivity advantage: sparing broad acetyltransferases such as GCN5L2, reducing systemic toxicity risk.

• Telomere & aging benefits: elongated telomeres and reversal of epigenetic drift in accelerated-aging models.

• Functional in vivo outcomes: ~50% tumor volume reduction and elimination of chemotherapy-related mortality in aggressive prostate cancer models.

Together, these findings support Telomir-1’s emerging profile as a broad-spectrum epigenetic and metabolic reset therapy with potential applications across oncology, neurodegeneration, autoimmune disease, metabolic dysfunction, and aging.

Next Steps

Telomir is advancing Telomir-1 through preclinical development and IND-enabling studies. Additional evaluations are underway in prostate cancer and other aggressive tumor models where epigenetic silencing and metabolic dysfunction drive metastasis and treatment resistance.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a preclinical-stage biotechnology company developing small-molecule therapies that target the root causes of cancer, aging, and age-related diseases by resetting dysregulated epigenetic programs. The Company’s lead candidate, Telomir-1, is being advanced across oncology and longevity indications based on its differentiated ability to restore tumor suppressors, block undruggable enzymes, and reprogram gene control. For more information, visit www.telomirpharma.com.

Cautionary Note Regarding Forward-Looking Statements

This press release, statements of Telomir’s management or advisors related thereto, and the statements contained in the news story linked in this release contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.

Any forward-looking statements in this press release are based on Telomir’s current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir’s programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which are on file with the SEC and available at www.sec.gov. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact Information

Helga Moya
info@telomirpharma.com
(786) 396-6723

SOURCE: Telomir Pharmaceuticals, Inc

View the original press release on ACCESS Newswire

TORONTO, ONTARIO / ACCESS Newswire / October 7, 2025 / New Horizon Aircraft (NASDAQ:HOVR), doing business as Horizon Aircraft (“Horizon Aircraft” or the “Company”), an advanced aerospace engineering company and developer of one of the world’s first hybrid eVTOL (electric Vertical Take-Off and Landing) aircraft, announces that management will participate in the following conferences in October:

Event: NBAA Business Aviation Convention & Exhibition (NBAA-BACE) 2025

Date: October 14-16, 2025

Location: Las Vegas – Las Vegas Convention Center, West Hall

Link: https://nbaa.org/events/2025-nbaa-business-aviation-convention-exhibition-nbaa-bace/

Management of the Company will be available for 1×1 meetings during the conference.

Event: Growth Frontiers Americas – New York 2025

Date: October 15-16, 2025

Location: New York City – 3 West Club

Link: https://www.growthfrontiersevents.com/conferences/new-york/

Management of the Company will be available for 1×1 meetings during the conference.

Event: Planet MicroCap Showcase: Toronto 2025

Date: October 22-23, 2025

Location: Toronto – The Arcadian Court & Loft

Link: PlanetMicroCap Webcast

Management will deliver a live presentation on October 22 at 11am ET and participate in 1×1 investor meetings throughout the two-day conference. Investors should register at the above link for access to the presentation webcast.

Event: DAIR To Innovate 2025

Date: October 23, 2025

Location: Toronto – Centennial College Downsview Campus

Link: https://www.dairhub.com/dair-to-innovate-2025-event/

The Company is a Platinum Sponsor of this Canadian aerospace industry conference and will be showcasing its large-scale prototype along with having a booth at the event’s Tech Showcase. Management will participate in informal discussions.

Event: Air Medical Transport Conference 2025

Date: October 27-29, 2025

Location: Omaha – CHI Health Convention Center

Link: https://www.amtc25.aams.org/

Management of the Company will be available for 1×1 meetings during the conference.

Event: Canadian Aerospace Summit 2025

Date: October 28-29, 2025

Location: Ottawa – Rogers Centre

Link: https://aiac.ca/events/canadian-aerospace-summit-2025/

Management of the Company will be available for 1×1 meetings during the conference.

About Horizon Aircraft

Horizon Aircraft (NASDAQ:HOVR) is an advanced aerospace engineering company that is developing one of the world’s first hybrid eVTOL aircraft that is to be able to fly most of its mission exactly like a normal aircraft while offering industry-leading speed, range, and operational utility. Horizon Aircraft’s unique designs put the mission first and prioritize safety, performance, and utility. Horizon intends to successfully complete testing and certification of its Cavorite X7 eVTOL and then scale unit production to meet expected demand from regional operators, emergency service providers, and military customers.

Visit www.horizonaircraft.com for more information.

Contacts

Investors:

Matt Chesler, CFA
FNK IR
(646) 809-2183
HOVR@fnkir.com

Media:

Edwina Frawley-Gangahar
EFG Media Relations
+44 7580 174672
edwina@efgmediarelations.com

SOURCE: Horizon Aircraft

View the original press release on ACCESS Newswire

EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A PANEL DISCUSSION

The Summit theme “unlocking the $1 Trillion Wealth transfer in Dubai”

PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / October 7, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that it will present at the Family Office Summit in Dubai with the theme of “Unlocking the $1 Trillion Wealth Transfer in Dubai”.

Panel Discussion Event Details

Date: October 9, 2025
Time: 11:20-11:50 a.m. local time
Location: Park Hyatt, Dubai

The summit will bring together thought leaders, opinion makers, executives and entrepreneurs from around the world to deliberate on unlocking the wealth transfer in Dubai.

Dr. Raza Bokhari, Medicus’s Executive Chairman & CEO, in his presentation, will focus on innovation in biotech/life sciences sector, the role of Artificial intelligence (AI) in drug development as well as the United Arab Emirates (UAE) Genomic project as an untapped differentiator.

Additional information on the Family Office Summit is available on the event website at https://familyofficesummit.ae/dubai/.

Medicus is currently conducting a Phase 2 clinical study for SKNJCT-003 in nine (9) clinical sites across the United States which commenced randomizing patients in August 2024. SKNJCT-003 is a double blinded, placebo controlled triple arm proof of concept Phase 2 clinical study, designed to non-invasively treat basal cell carcinoma (BCC) of the skin using novel, patent protected, dissolvable Doxorubicin-containing microneedle arrays (D-MNA). In March 2025, the Company announced a positively trending interim analysis for SKNJCT-003 demonstrating more than 60% clinical clearance. The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed.In April 2025, the investigational review board approved to increase the number of participants in SKNJCT-003 to ninety (90) subjects. The Company is expanding its trial sites in Europe and has randomized more than 75% of the ninety (90) participants expected to be randomized in the study. In September 2025, the company received positive feedback from the Food and Drug Administration (FDA) regarding its Type C meeting supporting the development of Skinject, indicating that the company may follow 505(b)(2) regulatory pathway to non-invasively treat BCC using dissolvable D-MNA.

The Company also has a clinical study (SKNJCT-004) currently underway in the United Arab Emirates (UAE). The study is expected to randomize thirty-six (36) patients in six (6) sites in the UAE. Cleveland Clinic Abu Dhabi (CCAD) is the principal investigator, along with Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), Rashid Hospital (RH), Clemenceau Medical Center (CMC) and American Hospital of Dubai (AHD). Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company.

In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

For further information contact:

Carolyn Bonner, President and Acting Chief Financial Officer
(610) 636-0184
cbonner@medicuspharma.com

Anna Baran-Djokovic, SVP Investor Relations
(305) 615-9162
adjokovic@medicspharma.com

About Medicus Pharma Ltd.

Medicus Pharma Ltd. (Nasdaq: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is actively engaged in multiple countries, spread over three continents.

SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd., is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The Company completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the United Arab Emirates.

In August 2025, the Company announced its entry into a non-binding memorandum of understanding (the “MoU”) with Helix Nanotechnologies, Inc. (“HelixNano”), a Boston Based biotech company focused on developing a proprietary advanced mRNA platform, in respect of their shared mutual interest in the development or commercial arrangement contemplated by the MoU. The MoU is non-binding and shall not be construed to obligate either party to proceed with a joint venture or any further development or commercial arrangement, unless and until definitive agreements are executed.

In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

In September 2020, Antev completed a Phase 1 clinical trial in which Teverelix was shown to be well tolerated with no dose-limiting toxicities and demonstrated rapid testosterone suppression. The study included 48 healthy male volunteers. In February 2023, Antev also completed a Phase 2a study in fifty (50) patients with advanced prostate cancer (APC), where Teverelix achieved the primary endpoint of greater than 90% probability of castration levels of testosterone suppression (97.5%) but the secondary endpoint of maintaining this rate above 90% was not met with the probability dropping to 82.5% by Day 42.

In January 2023, the FDA, reviewed the Phase 1 and Phase 2a data and provided written guidance on Antev’s proposed Phase 3 trial design for Teverelix. This milestone supports the Company’s clinical plans to develop Teverelix as a treatment for advanced prostate cancer patients with increased cardiovascular risk.

In December 2023, FDA approved the Phase 2b study design in advanced prostate cancer covering 40 patients.

In November 2024, FDA approved the Phase 2b study design in acute urinary retention covering 390 patients.

Cautionary Notice on Forward-Looking Statements

Certain information in this news release constitutes “forward-looking information” under applicable securities laws. “Forward-looking information” is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, the development of Teverelix and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix for AURr and high CV risk prostate cancer, and the potential market opportunities related thereto, the MOU, including the potential signing of definitive agreements between Medicus and HelixNano and the development of thermostable infectious diseases vaccines by combining HelixNano’s proprietary mRNA vaccine platform with Medicus’s proprietary microneedle array (MNA) delivery platform, the Company’s aim to fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof, plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of SkinJect through SKNJCT-003 and SKNJCT-004, and the potential market opportunities related thereto, the commencement of the SKNJCT-004 study and the potential results of and benefits of such study. Forward-looking statements are often but not always, identified by the use of such terms as “may”, “on track”, “aim”, “might”, “will”, “will likely result”, “could,” “designed,” “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek”, “continue”, “target”, “potential” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s annual report on form 10-K for the year ended December 31, 2024 (the “Annual Report”), and in the Company’s other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company’s common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

SOURCE: Medicus Pharma Ltd

View the original press release on ACCESS Newswire

BUDD LAKE, NJ / ACCESS Newswire / October 7, 2025 / EMCORE LLC, a leading provider of advanced inertial sensors serving the aerospace and defense industries, today announced the launch of the TAC-DSP-1750 Fiber Optic Gyroscope (FOG). The new TAC-DSP-1750 marks the return of a proven industry favorite, the legacy DSP-1750, now re-engineered with EMCORE’s state-of-the-art Photonic Integrated Chip (PIC) technology and modernized electronics for higher performance, improved reliability, and expanded applications.

The TAC-DSP-1750 series includes both single and dual-axis tactical-grade FOGs designed for demanding commercial and military platforms. It launches as the smallest high-performance single or dual-axis FOG available in the marketplace today, delivering exceptional precision in an ultra-compact form factor that opens new possibilities for size, weight, and power-constrained systems.

With its compact, lightweight housing and lower power electronics, the new design enhances performance while expanding deployment possibilities across autonomous and stabilized systems. Featuring EMCORE’s proprietary PIC Inside design, the TAC-DSP-1750 delivers exceptional bias stability and low noise (VRW) performance through advanced photonic gyro design. It offers outstanding environmental robustness, including superior shock and vibration tolerance, flexible integration with common power and communication interfaces, and backward compatibility with the legacy DSP-1750 to ensure a smooth upgrade path for existing users.

The TAC-DSP-1750 builds upon EMCORE’s proven TAC-450 tactical platform, sharing common software, electronics, and circuit boards for simplified integration and logistics across the TAC product family.

Designed for today’s most challenging applications including autonomous vehicles, drones, AUVs, ROVs, and platform stabilization systems, the TAC-DSP-1750 offers engineers multiple configuration options to meet precise performance requirements across transportation, defense, agriculture, construction, and mining industries.

“The DSP-1750 has been one of the most trusted unhoused FOGs in the industry,” Zach Lincolnhol, VP Sales & Marketing, EMCORE. “By combining that proven foundation with our latest PIC technology, the new TAC-DSP-1750 delivers modern performance in a familiar form factor, bringing time-tested performance into a new era of technology.”

For more information about EMCORE’s TAC-DSP-1750 Fiber Optic Gyroscopes and the complete TAC product line, visit https://www.emcore.com

CONTACT:

Kenneth Machado
kenneth_machado@emcore.com

SOURCE: EMCORE Corporation

View the original press release on ACCESS Newswire